rituksimabi

Rituksimabi is a term that does not correspond to a widely documented therapeutic agent in standard medical references. In publicly available pharmacology databases and regulatory records, there is no approved drug or well-established investigational product named rituksimabi. The term may represent a typographical error or transliteration of rituximab, a well-known anti-CD20 monoclonal antibody, or it may be used as a fictional or provisional designation in unpublished materials or speculative writing.

If rituksimabi appears in a specific document or context, the exact meaning should be confirmed with that source. In general, rituximab—if this is the intended reference—is a chimeric monoclonal antibody used to treat certain B-cell malignancies and autoimmune diseases. It binds CD20 on B cells and can mediate cell death through mechanisms such as antibody-dependent cellular cytotoxicity and complement activation. Rituximab is approved in many countries for multiple indications and has a well-established clinical profile and safety considerations.

Because reliable public information about rituksimabi itself is lacking, readers should consult authoritative pharmacology resources or the original source for clarification. See also rituximab.